Suls Jerry M, Alfano Catherine, Yap Christina
Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health; Manhasset, NY, USA.
Northwell Health Cancer Institute; Manhasset, NY, USA.
Harv Data Sci Rev. 2022;4(SI3). doi: 10.1162/99608f92.d99e6ff5. Epub 2022 Sep 8.
Treatment of patients who suffer from concurrent health conditions is not well served by (1) evidence-based clinical guidelines that mainly specify treatment of single conditions and (2) conventional randomized controlled trials (RCTs) that identify treatments as safe and effective on . Clinical decision-making based on the average patient effect may be inappropriate for treatment of those with multimorbidity who experience burdens and obstacles that may be unique to their personal situation. We describe how the personalized (N-of-1) trials can be integrated with an automatic platform and virtual/remote technologies to improve patient-centered care for those living with multimorbidity. To illustrate, we present a hypothetical clinical scenario-survivors of both coronavirus disease 2019 (COVID-19) and cancer who chronically suffer from sleeplessness and fatigue. Then, we will describe how the four standard phases of conventional RCT development can be modified for personalized trials and applied to the multimorbidity clinical scenario, outline how personalized trials can be adapted and extended to compare the benefits of personalized trials versus between-subject trial design, and explain how personalized trials can address special problems associated with multimorbidity for which conventional trials are poorly suited.
对于患有多种并发健康状况的患者,以下两种情况无法很好地满足其治疗需求:(1)主要规定单一疾病治疗方法的循证临床指南;(2)将治疗确定为对……安全有效的传统随机对照试验(RCT)。基于平均患者效果的临床决策可能不适用于患有多种疾病的患者,他们会经历一些可能因个人情况而异的负担和障碍。我们描述了如何将个性化(单病例)试验与自动平台以及虚拟/远程技术相结合,以改善对患有多种疾病患者的以患者为中心的护理。为了说明这一点,我们展示了一个假设的临床场景——2019年冠状病毒病(COVID-19)和癌症的幸存者,他们长期遭受失眠和疲劳的困扰。然后,我们将描述传统RCT开发的四个标准阶段如何针对个性化试验进行修改并应用于多种疾病的临床场景,概述个性化试验如何进行调整和扩展以比较个性化试验与受试者间试验设计的益处,并解释个性化试验如何解决与多种疾病相关的特殊问题,而传统试验对此并不适用。